Empowered Patient Podcast

Alana McGolrick DNP is the Chief Nursing Officer at PeriGen and focused on reducing preventable maternal and newborn deaths using technology and AI to support labor and delivery activities. The PeriWatch Vigilance platform removes bias and provides objective assessment to those clinicians and physicians monitoring the physiological changes in patients and their fetuses.

Alana explains, "I have been a fetal monitoring geek for my entire life in labor and delivery. I've always been fascinated with the labor and delivery process. When we do monitor our patients, we put these monitors on the patient's abdomen, so on their pregnant belly, and we're looking at uterine contractions, we're looking at the fetal heart rate. Then we're also monitoring mom's vital signs and how she's progressing in labor."

"There's a number of different factors that we analyze while we're in the intrapartum stage, labor, and delivery, watching how our patient is progressing. One of our patients happens to be invisible, right? We only have the fetal heart rate as a sign of wellbeing or some sort of duress. They can go in the exact opposite direction for us."

@PeriGen #PeriWatch #PeriWatchVigilance #MaternalMortality #NewbornMortality #AI #LaborandDelivery

PeriGen.com

Listen to the podcast here

Alana McGolrick DNP is the Chief Nursing Officer at PeriGen and focused on reducing preventable maternal and newborn deaths using technology and AI to support labor and delivery activities. The PeriWatch Vigilance platform removes bias and provides objective assessment to those clinicians and physicians monitoring the physiological changes in patients and their fetuses.

Alana explains, "I have been a fetal monitoring geek for my entire life in labor and delivery. I've always been fascinated with the labor and delivery process. When we do monitor our patients, we put these monitors on the patient's abdomen, so on their pregnant belly, and we're looking at uterine contractions, we're looking at the fetal heart rate. Then we're also monitoring mom's vital signs and how she's progressing in labor."

"There's a number of different factors that we analyze while we're in the intrapartum stage, labor, and delivery, watching how our patient is progressing. One of our patients happens to be invisible, right? We only have the fetal heart rate as a sign of wellbeing or some sort of duress. They can go in the exact opposite direction for us."

@PeriGen #PeriWatch #PeriWatchVigilance #MaternalMortality #NewbornMortality #AI #LaborandDelivery

PeriGen.com

Download the transcript here

Rosemary Kennedy is the Chief Health Information Officer at Connect America, where data collection, predictive analytics, remote monitoring, human intervention, and promotion of patient care circles are all part of the solution for keeping seniors out of the hospital and independent as possible.

Rosemary explains, "There are probably three areas in terms of them achieving your goal and living independently and safely in your home. And you've identified one of them, this connected care management platform in the home that involves a system of integrated technologies."

"We see that one in every ten admissions to the hospital are related to the fact that individuals are not adherent to their medication regimen. The second area is in interaction with their care circles and using technology for that. We have seen with COVID that individuals want to be connected to family, friends, neighbors. They want to do it in an easy way, and this includes voice video chat that they can interoperate with the people that are important to them in terms of needs related to food, support, transportation."

#ConnectedHealth #SeniorHealthcare #ConnectedCare #RPM #COVID19 #HealthTech

ConnectAmerica.com

Listen to the podcast here

Rosemary Kennedy is the Chief Health Information Officer at Connect America, where data collection, predictive analytics, remote monitoring, human intervention, and promotion of patient care circles are all part of the solution for keeping seniors out of the hospital and independent as possible.

Rosemary explains, "There are probably three areas in terms of them achieving your goal and living independently and safely in your home. And you've identified one of them, this connected care management platform in the home that involves a system of integrated technologies."

"We see that one in every ten admissions to the hospital are related to the fact that individuals are not adherent to their medication regimen. The second area is in interaction with their care circles and using technology for that. We have seen with COVID that individuals want to be connected to family, friends, neighbors. They want to do it in an easy way, and this includes voice video chat that they can interoperate with the people that are important to them in terms of needs related to food, support, transportation."

#ConnectedHealth #SeniorHealthcare #ConnectedCare #RPM #COVID19 #HealthTech

ConnectAmerica.com

Download the transcript here

Andy Kidd MD is the President and COO and soon to be CEO of Aptinyx. With a focus on Pain Awareness Month, Andy provides a view into the world of treating long-term chronic pain and the necessary innovations to treat the cause of chronic pain in conditions like diabetic peripheral neuropathy and fibromyalgia.

Andy explains, "So we've discovered and are developing a new drug that has a new mechanism for chronic pain. And actually, it really takes that problem of what is happening in the brain head-on because our drug works in the brain, particularly in the part of the brain called the prefrontal cortex. That is really responsible for how we control and regulate our behavior, what we pay attention to, what we don't pay attention to, how our emotions are affected by things that we're sensing in the environment, and things like that. So we are really trying to tackle this part of the chronic pain problem that has been probably under-recognized in the past and for which there really aren't any good therapies right now."

"The goal would be that our drug works as it is supposed to, and it works on a receptor called the NMDA receptor in the brain, which is basically responsible for how the brain cells communicate and connect to each other. By boosting its activity, the goal would be to restore normal function, some of these parts of the brain that may then help the patient reduce the perception of pain. It may help the patient with some of the consequences of the pain around those things like sleep and mood and cognition."

@Aptinyx #PainAwarenessMonth #NMDA #CNS #Brain #Innovation #PainTherapies #PTSD #ChronicPain #CognitiveImpairment

Aptinyx.com

Download the transcript here

Andy Kidd MD is the President and COO and soon to be CEO of Aptinyx. With a focus on Pain Awareness Month, Andy provides a view into the world of treating long-term chronic pain and the necessary innovations to treat the cause of chronic pain in conditions like diabetic peripheral neuropathy and fibromyalgia.

Andy explains, "So we've discovered and are developing a new drug that has a new mechanism for chronic pain. And actually, it really takes that problem of what is happening in the brain head-on because our drug works in the brain, particularly in the part of the brain called the prefrontal cortex. That is really responsible for how we control and regulate our behavior, what we pay attention to, what we don't pay attention to, how our emotions are affected by things that we're sensing in the environment, and things like that. So we are really trying to tackle this part of the chronic pain problem that has been probably under-recognized in the past and for which there really aren't any good therapies right now."

"The goal would be that our drug works as it is supposed to, and it works on a receptor called the NMDA receptor in the brain, which is basically responsible for how the brain cells communicate and connect to each other. By boosting its activity, the goal would be to restore normal function, some of these parts of the brain that may then help the patient reduce the perception of pain. It may help the patient with some of the consequences of the pain around those things like sleep and mood and cognition."

@Aptinyx #PainAwarenessMonth #NMDA #CNS #Brain #Innovation #PainTherapies #PTSD #ChronicPain #CognitiveImpairment

Aptinyx.com

Listen to the podcast here

Jessica Magana is the Product Manager of Lightbeam Health Solutions, a population health management company. Jessica shines a light on the biggest changes coming from CMS in risk adjustment for Medicare Advantage in 2022. Organizations need to understand the technical requirements behind the way diagnosed base risk scores will be calculated and the impact of delayed healthcare due to COVID-19.

Jessica explains, "Lightbeam is a platform that facilitates end-to-end population health management for our ACOs, payers, provider groups, health systems, and some other healthcare organizations. Just some highlights about the platform and what it provides are provider alignment, tools for engagement, and satisfaction rates. It allows for some two-way information sharing. It has been proven to lower utilization rates and improve risk and coding opportunities; it also helps to improve quality scores for HEDIS and Star measures."

"Another important change that I think is very important is around some of the quality bonus program changes. Due to COVID-19, a public health emergency has been awarded. CMS is now promoting some new changes that are going to impact some of those Star ratings."

@LightbeamHealth #LightbeamHealth #assessment #caremanagement #Healthcare #HealthIT #Payer #PayerProvider #PopHealth #PopulationHealth #referral #VBC #MedicareAdvantage #MA #COVID19

Lightbeamhealth.com

Listen to the podcast here

Jessica Magana is the Product Manager of Lightbeam Health Solutions, a population health management company. Jessica shines a light on the biggest changes coming from CMS in risk adjustment for Medicare Advantage in 2022. Organizations need to understand the technical requirements behind the way diagnosed base risk scores will be calculated and the impact of delayed healthcare due to COVID-19.

Jessica explains, "Lightbeam is a platform that facilitates end-to-end population health management for our ACOs, payers, provider groups, health systems, and some other healthcare organizations. Just some highlights about the platform and what it provides are provider alignment, tools for engagement, and satisfaction rates. It allows for some two-way information sharing. It has been proven to lower utilization rates and improve risk and coding opportunities; it also helps to improve quality scores for HEDIS and Star measures."

"Another important change that I think is very important is around some of the quality bonus program changes. Due to COVID-19, a public health emergency has been awarded. CMS is now promoting some new changes that are going to impact some of those Star ratings."

@LightbeamHealth #LightbeamHealth #assessment #caremanagement #Healthcare #HealthIT #Payer #PayerProvider #PopHealth #PopulationHealth #referral #VBC #MedicareAdvantage #MA #COVID19

Lightbeamhealth.com

Download the transcript here

Dr. Hugh Rienhoff is the Founder and Chief Executive Officer at Imago BioSciences. He and his team are developing their lead asset bomedemstat for the treatment of myeloproliferative neoplasms (MPNs) which are rare blood cancers.

Hugh explains, "So MPNs, myeloproliferative neoplasms, are actually a family of diseases that include myelofibrosis, polycythemia vera, and essential thrombocythemia. And they're all characterized by an elevation of one element in the blood or another different cell type."

"But they're all related in the sense that they share a family of very limited mutations. And those mutations, in one of three genes, typically arise in patients who are in their 50s or 60s and those mutations occur in the blood stem cells."

"They're not hereditary, typically. They're what we call somatic mutations arising in blood stem cells. And they are called neoplastic diseases, which is a Greek name for cancer, but they typically are much more indolent than your typical bone marrow cancers, like leukemia, which are almost fulminant by comparison."

@Imagobiorx #ImagoBioSciences #MPN #MPNSM #EssentialThrombocythemia #myelofibrosis #bomedemstat #LSD1 #BloodCancer #RareDisease

ImagoBio.com

Listen to the podcast here

Dr. Hugh Rienhoff is the Founder and Chief Executive Officer at Imago BioSciences. He and his team are developing their lead asset bomedemstat for the treatment of myeloproliferative neoplasms (MPNs) which are rare blood cancers.

Hugh explains, "So MPNs, myeloproliferative neoplasms, are actually a family of diseases that include myelofibrosis, polycythemia vera, and essential thrombocythemia. And they're all characterized by an elevation of one element in the blood or another different cell type."

"But they're all related in the sense that they share a family of very limited mutations. And those mutations, in one of three genes, typically arise in patients who are in their 50s or 60s and those mutations occur in the blood stem cells."

"They're not hereditary, typically. They're what we call somatic mutations arising in blood stem cells. And they are called neoplastic diseases, which is a Greek name for cancer, but they typically are much more indolent than your typical bone marrow cancers, like leukemia, which are almost fulminant by comparison."

@Imagobiorx #ImagoBioSciences #MPN #MPNSM #EssentialThrombocythemia #myelofibrosis #bomedemstat #LSD1 #BloodCancer #RareDisease

ImagoBio.com

Download the transcript